Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025
Rhea-AI Summary
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment, will host its Q2 2025 earnings conference call on August 13, 2025, at 8:00 a.m. ET. The company will provide business updates and financial results for the quarter ended June 30, 2025.
Investors can access the call via phone at 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast will be available on Mersana's website, with a replay accessible for approximately 90 days after the call.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, MRSN declined 4.83%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2025 on Wednesday, August 13, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that have generated a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.
Contact:
Mersana@argotpartners.com
FAQ
When is Mersana Therapeutics (MRSN) Q2 2025 earnings call?
How can investors access Mersana Therapeutics Q2 2025 earnings call?
How long will the MRSN Q2 2025 earnings call replay be available?
What does Mersana Therapeutics (MRSN) specialize in?
